About NX Prenatal
NX Prenatal is a company based in Louisville (United States) founded in 2010 by Brian Brohman. It operates as a HealthTech. NX Prenatal has raised $5.76 million across 5 funding rounds from investors including Johnson & Johnson Innovation. NX Prenatal offers products and services including Preterm Birth Testing, Preeclampsia Detection, and Placenta Accreta Detection. NX Prenatal operates in a competitive market with competitors including Sera Prognostics, Mirvie, Pregnolia, DotLab and Yourgene Health, among others.
- Headquarter Louisville, United States
- Founders Brian Brohman
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Nx Prenatal Inc.
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$5.76 M (USD)
in 5 rounds
-
Latest Funding Round
$3.13 M (USD), Series A
Aug 21, 2023
- Investors
-
Employee Count
Not available
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of NX Prenatal
NX Prenatal offers a comprehensive portfolio of products and services, including Preterm Birth Testing, Preeclampsia Detection, and Placenta Accreta Detection.
Blood tests for preterm birth risk are provided early.
Early detection of preeclampsia risk is enabled through testing.
Technology for detecting placenta accreta is offered accurately.
People of NX Prenatal
Unlock access to complete
Unlock access to complete
Funding Insights of NX Prenatal
NX Prenatal has successfully raised a total of $5.76M across 5 strategic funding rounds. The most recent funding activity was a Series A round of $3.13 million completed in August 2023. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in NX Prenatal
NX Prenatal has secured backing from 1 investor, including institutional investors. Prominent investors backing the company include Johnson & Johnson Innovation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
-
|
Locked | Locked | Locked |
Investor details for NX Prenatal
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by NX Prenatal
Investment portfolio details for NX Prenatal
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - NX Prenatal
Detailed financials for NX Prenatal
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Nx Prenatal Comparisons
Peer comparison for NX Prenatal
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of NX Prenatal
NX Prenatal operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Sera Prognostics, Mirvie, Pregnolia, DotLab and Yourgene Health, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Sera Prognostics is focused on women's health diagnostics.
|
|
| Locked | Locked | Locked |
Non-invasive blood tests for prenatal fetal health predictions are offered.
|
|
| Locked | Locked | Locked |
Preterm birth risks are predicted using cervical stiffness measurement devices.
|
|
| Locked | Locked | Locked |
Molecular diagnostic testing for endometriosis is provided via saliva-based biomarkers.
|
|
| Locked | Locked | Locked |
Non-invasive prenatal genetic tests and genomic services are provided.
|
|
| Locked | Locked | Locked |
Digital women's health management software for employers and individuals
|
Detailed competitors of NX Prenatal
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Nx Prenatal
Complete news archive for NX Prenatal
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about NX Prenatal
NX Prenatal was founded in 2010 and raised its 1st funding round 7 years after it was founded.
NX Prenatal is headquartered in Louisville, United States. It is registered at Louisville, Kentucky, United States.
Brian Brohman is the current CEO of NX Prenatal. They have also founded this company.
NX Prenatal is a funded company, having raised a total of $5.76M across 5 funding rounds to date.
NX Prenatal is engaged in advancing maternal and fetal health by developing molecular blood tests. These tests are designed to provide early insights into conditions such as preterm birth, preeclampsia, and placenta accreta. The company collaborates with leading institutions to enable personalized healthcare delivery in the maternal-fetal medicine sector. Solutions are aimed at reducing complications and improving outcomes for mothers and babies through early detection and tailored health strategies.
NX Prenatal's top competitors include Mirvie, Syrona Health and DotLab.
NX Prenatal offers Preterm Birth Testing, Preeclampsia Detection, and Placenta Accreta Detection.
NX Prenatal has 1 investor. Key investors include Johnson & Johnson Innovation.